Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

App aims to educate women on HPV and breast cancer

NCT ID NCT07471113

First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 10 times

Summary

This study tested whether a mobile app-based education program could improve women's understanding of HPV and their attitudes toward breast cancer screening. Seventy women aged 30-65 used the app and completed surveys before and after the program. The goal was to see if the app could increase HPV literacy and encourage more positive beliefs about screening.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Atatürk University

    Erzurum, 25240, Turkey (Türkiye)

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mobile application

What this could lead to

If successful, this could show that a simple mobile app can boost women's understanding of HPV and encourage them to get screened for breast cancer.

What could go wrong

This is a small, completed study with only 70 participants, so results may not apply to all women. It measures knowledge and beliefs, not actual cancer prevention or detection.

Conditions

The condition(s) this trial relates to.

breast neoplasm human papilloma virus infection Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.